L.S. EFREMOVA, L.V. VASILIEVA, E.V. GOSTEVA

 Voronezh State Medical University named after N.N. Burdenko, Voronezh

 Contact details:

Efremova L.S. — post-graduate student of the Department of Propaedeutics of Internal Diseases

Address: 10 Studencheskaya St., Voronezh, Russian Federation, 394036, tel.: +7-903-858-22-00, e-mail: ljudmilarogowa@yandex.ru

The purpose — to study the association of lipoprotein-associated phospholipase A2 (LP-PLA2) inflammatory biomarkers and tumor necrosis factor-alpha (TNF-α) with indicators of carbohydrate and lipid metabolism in the progression of chronic heart failure with moderately reduced ejection fraction (HFmrEF) in patients with diabetes mellitus (DM).

Material and methods. 78 patients with established diagnosis of DM and HFmrEF (EF = 41–49%), functional class (FC) of CHF I and II according to NYHA were examined. The patients underwent examination of carbohydrate and lipid metabolism, serum levels of LP-PLA2 and TNF-a. Two groups of patients were formed: the 1^st group — patients with HFmrEF and DM who had myocardial infarction (MI), 37 people (47.4%), the 2^nd group — patients with HFmrEFand DM, 41 people (52.6%).

Results. An increase in the content of LP-PLA2 and TNF-a with an increase in CHF FC was revealed. In the 1^st group, the levels of inflammation biomarkers, insulin, HOMA-IR, total cholesterol, low density lipoproteins significantly exceeded those in the 2^nd group. A positive correlation was found between the levels of LP-PLA2 and TNF-a and the parameters of carbohydrate and lipid metabolism.

Conclusion. The progression of DM and HFmrEF is accompanied by an increase in chronic inflammation and an increase in the content of Lp-PLA2 and TNF-a with an increase in CHF FC. The association of elevated levels of inflammatory biomarkers with carbohydrate and lipid metabolism is an additional factor of HFmrEF progression in patients with DM. An increase in the serum levels of inflammatory biomarkers in patients with HFmrEF and DM who underwent MI, compared with patients with HFmrEF and DM, makes it possible to use LP-PLA2 and TNF-a for diagnosing complications in patients with DM and HFmrEF.

Key words: chronic heart failure, diabetes mellitus, biomarkers, lipoprotein-associated phospholipase A2, tumor necrosis factor-alpha.

REFERENCES

1. Mamedov M.N., Bondarenko I.Z., Mareev Yu.V., Kanorskiy C.G., Khalimov Yu.Sh., Agafonov P.V. New position on chronic heart failure of the Association for Heart Failure of the European Society of Cardiology in Patients with Diabetes Mellitus: comments by Russian experts. Mezhdunarodnyy zhurnal serdtsa i sosudistykh zabolevaniy, 2018, no. 20, pp. 43–50 (in Russ.). DOI: 10.24412/2311-1623-2018-20-43-50
2. Dunlay S.M., Givertz M.M., Aguilar D. et al. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/ HFSA heart failure guideline update. Circulation, 2019, vol. 140 (7), rr. 294–324. DOI: 10.1161/ CIR.0000000000000691
3. Kobalava Zh.D., Eshniyazov N.B., Medovshchikov V.V. et al. Type 2 diabetes mellitus and heart failure: innovative possibilities for prognosis management. Kardiologiya, 2019, vol. 59, no. 4, pp. 76–87 (in Russ.). DOI: 1018087/ cardio.2019.410253
4. Topolyanskaya S.V. Tumor necrosis factor-alpha and age-associated pathology. Arkhiv vnutrenney meditsiny, 2020, vol. 10, no. 6, pp. 414–421 (in Russ.). DOI: 10.20514/2226-6704-2020-10-6-414-421
5. Svarovskaya A.V., Teplyakov A.T., Gusakova A.M., Garganeeva A.A. The role of markers of inflammation and endothelial dysfunction in the prognosis of the development of cardiovascular complications in patients with coronary artery disease and metabolic syndrome who underwent coronary stenting. Kardiologiya, 2020, vol. 60, no. 8, pp. 98–105 (in Russ.). DOI: 10.18087/cardio.2020.8.n966
6. Tereshchenko I.V., Kayushev P.E. Tumor necrosis factor-α and its role in pathology. RMZh. Meditsinskoe obozrenie, 2022, vol. 6, no. 9, pp. 523–527 (in Russ.). DOI: 10.32364/2587-6821-2022-6-9-523-527
7. Kany S., Vollrath J.T., Relja B. Cytokines in inflammatory disease. International Journal of Molecular Sciences, 2019, vol. 20 (23), r. 6008. DOI: 10.3390/ijms20236008
8. Efremova L.S., Vasil’eva L.V., Gosteva E.V. Association of aldosterone, tissue inhibitor of matrix metalloproteinases-1 and tumor necrosis factor-alpha with myocardial remodeling in patients with chronic heart failure and diabetes mellitus. Kardiologiya v Belarusi, 2022, vol. 14, no. 5, pp. 587–595 (in Russ.). Doi: 10.34883/PI.2022.14.5.005
9. Khazova E.V., Bulashova O.V., Oslopov V.N., Malkova M.I., Zaplatova D.A., Kolpakova E.A., Gazizyanova V.M. Tumor necrosis factor a-marker of systemic inflammation in patients with heart failure. Prakticheskaya meditsina, 2017, no. 2, pp. 24–27 (in Russ.).
10. Rolski F., Błyszczuk P. Complexity of TNF-α Signaling in Heart Disease. J Clin Med, 2020, vol. 9 (10), rr. 3267. DOI: 10.3390/jcm9103267
11. Efremova L.S., Vasil’eva L.V., Gosteva E.V. Significance of a tissue inhibitor of matrix metalloproteinases-1 and tumor necrosis factor alpha for the diagnosis of progression of chronic heart failure in patients with diabetes mellitus. Meditsinskiy al’manakh, 2021, vol. 4, no. 69, pp. 48–54 (in Russ.).
12. Schumacher S.M., Naga Prasad S.V. Tumor Necrosis Factor-a in Heart Failure: An updated review. Curr Cardiol Rep, 2018, vol. 20 (11), rr. 117. DOI: 10.1007/s11886-018-1067-7
13. Osmankulova G.E., Noruzbaeva A.M. Lipoprotein-associated phospholipase A2 in patients with coronary heart disease and metabolic syndrome. Kardiologicheskiy vestnik, 2016, vol. 11, no. 1, pp. 34–37 (in Russ.). DOI: 10.18565/cardio.2016.1.49-50
14. Abdullah S.M., Defina L.F., Leonard D. et al. Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease. Circulation, 2018, vol. 138 (21), rr. 2315–2325. DOI: 10.1161/CIRCULATJONAHA. 118.034273
15. Akash M.S.H., Rehman K., Liaqat A. Tumor Necrosis Factor-Alpha: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus. J. Cell. Biochem, 2018, vol. 119 (1), rr. 105–110. DOI: 10.1002/jcb.26174
16. Huang F., Wang K., Shen J. Lipoprotein‐associated phospholipase A2: The story continues. Medicinal Research Reviews, 2020, vol. 40 (1), rr. 9–134. DOI: 10.1002/med.21597
17. Klimchuk A.V., Beloglazov V.A., Zayaeva A.A. et al. Atherosclerosis: immunological aspects of pathogenesis, the role of inflammation, therapeutic strategies, prospects for the use of nanotechnology. Tavricheskiy medikobiolog. vestnik, 2021, vol. 24, no. 3, rr. 77–89 (in Russ.). DOI: 10.37279/2070-8092-2021-24-3-77-89